Skip to main content

vVARDIS Holding AG

corporate_fare Company Profile

vVARDIS Holding AG

VVVV·NYSE·Industrial Applications And Services·CIK 0001907709

vVARDIS Holding AG is a high-growth Swiss dental medtech company based in Zug, specializing in non-invasive cavity treatment. The company develops and commercializes a peptide-enabled platform called Curodont™, designed to arrest or reverse early-stage tooth decay and preserve natural tooth structure. Curodont™ products, such as Curodont Repair Fluoride Plus (U.S.) and Curodont Repair (international markets), are applied chairside without drilling, needles, or anesthesia, and are intended to restore enamel integrity. This technology aims to fill a treatment gap between "watch-and-wait" and "drill-and-fill" approaches in dental care. vVARDIS distributes its products in the U.S. exclusively through Henry Schein. As of June 30, 2026, vVARDIS estimates its products have treated over 3.5 million teeth and have been sold into more than 20,000 general dental practices. The company's revenue includes sales of dental care products, with the majority derived from the United States, and the remainder from Switzerland, Italy, and the United Kingdom. vVARDIS was founded in 2020 and booked $50 million in revenue for the 12 months ended June 30, 2026. The company plans to list its Class A ordinary shares on the New York Stock Exchange under the ticker “VVVV.” Sources: [1] https://multiples.vc/private-comps/vvardis [2] https://mediaconnect.com/vvardis-announces-investment-from-apollo-achieves-unicorn-status [3] https://www.tradingview.com/news/tradingview:031ff130c2fe4:0-vvardis-non-invasive-dental-treatment-platform-files-for-nyse-ipo/ [4] https://www.ipocandy.com/vvardis-holding-ipo-deck/ [5] https://www.renaissancecapital.com/IPO-Center/News/122615/cavity-treatment-provider-vvardis-sets-terms-for-214-million-us-ipo [6] https://pitchbook.com/profiles/company/458026-39

vVARDIS Holding AG (NYSE:VVVV) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 2 items for VVVV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 7/10.

Recent high-impact activity:

  • vVardis Falls 22% in NYSE Debut After $175M IPO Priced Below Range
  • Swiss Dental Med-Tech vVARDIS Prices NYSE IPO at $18 a Share

Short Interest & Short Volume

On November 19, 2026, 82.2% of VVVV volume reported to FINRA trade-reporting facilities was marked short.

Daily short volume (FINRA facilities)82.2% of 152,321 shares on November 19, 2026
5-day average short volume38.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for VVVV, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.

1 recent capital raise

IPO Terms Confirmed · Net Proceeds to Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

$14.61 -2.63% today
52-week range · as of 2026-11-13 $14 – $15.27
Market cap
$299.58M
Live data · 2026-11-20 20:51 UTC · Market open

show_chartPrice Chart

Loading chart...

feed VVVV - Latest Insights

VVVV
Nov 13, 2026, 12:42 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $14.92
Real-time Price: $14.61 info
Change: -$0.315 (-2%) info
Market Cap: $299.577M info
VVVV
Nov 13, 2026, 12:02 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: N/A
Real-time Price: $14.61 info
Change: N/A info
Market Cap: $299.577M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets